B
Bulent Ozpolat
Researcher at University of Texas Health Science Center at Houston
Publications - 15
Citations - 8289
Bulent Ozpolat is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Cancer & Immune system. The author has an hindex of 8, co-authored 15 publications receiving 7644 citations. Previous affiliations of Bulent Ozpolat include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
MicroRNA-based Targeted Therapeutics in Pancreatic Cancer.
Nilgun Gurbuz,Bulent Ozpolat +1 more
TL;DR: The development of new targeted cancer therapies based on miRNAs promise to revolutionize cancer treatment due to their increased efficacy compared to conventional chemoradiation-based therapies and hopefully to lower levels of adverse effects.
Journal ArticleDOI
Immunoliposomes Containing Antibodies to Costimulatory Molecules as Adjuvants for HIV Subunit Vaccines
TL;DR: This strategy of incorporating antibodies to costimulatory molecules on the surface of antigen-containing particulates, such as liposomes or microspheres, can be used to increase DTH immune responses to protein or peptide vaccines.
Journal ArticleDOI
Quantitation of Helicobacter pylori in the stomach using quantitative polymerase chain reaction assays.
Bulent Ozpolat,Jeffrey K. Actor,Xiao Mei Rao,Sangjun Lee,Michael S. Osato,David Y. Graham,L. B. Lachman +6 more
TL;DR: In this paper, the authors developed quantitative assays using the polymerase chain reaction to assess the quantity of Helicobacter pylori in the gastric mucosa, which is thought to correlate with the degree of inflammation and thus indirectly with the outcome of infection.
Book ChapterDOI
Liposomal cytokines and liposomes targeted to costimulatory molecules as adjuvants for human immunodeficiency virus subunit vaccines.
Bulent Ozpolat,L. B. Lachman +1 more
TL;DR: The manipulation of the TCR-costimulatory receptor network offers therapeutic opportunities for the control of hyper-responsiveness, such as autoimmune diseases and for the controlled control of hyporesponsiveness as exhibited by a poor response to subunit vaccine antigens and tumor antIGens.
Book ChapterDOI
CHAPTER 16:Nanoparticle Delivery of miRNA in Cancer
TL;DR: Potential approaches for systemic delivery of miRNAs for cancer therapy are reviewed and nanocarriers used for the delivery ofmiRNAs into tumors are reviewed to focus on nanodelivery systems to overcome degradation of mi RNAs by nucleases, their low cellular uptake, immunogenicity, and rapid renal clearance.